A carregar...
Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management
Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines display a superior advantage because the nasal mucosa is often the initial site of infection. Preclinical and clinical studies concerning intranasal immunization elicit high neutralizing antibody generation and mucosal IgA...
Na minha lista:
| Publicado no: | Drug Discov Today |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier Ltd.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8319039/ https://ncbi.nlm.nih.gov/pubmed/34332100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drudis.2021.07.021 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|